“2-step MCI-AD”: a simple scoring system to predict rapid conversion from mild cognitive impairment to Alzheimer dementia

2021 ◽  
Vol 94 ◽  
pp. 104359
Author(s):  
Antonio Muscari ◽  
Fabio Clavarino ◽  
Vincenzo Allegri ◽  
Andrea Farolfi ◽  
Maria Macchiarulo ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Scoring System ◽  
Alzheimer Dementia ◽  
Rapid Conversion

Abstract 1122‐000036: Demographic and Pharmacological Characteristics of Alzheimer Dementia Patients with Mild Cognitive Impairment stratified by Gender

2021 ◽  
Vol 1 (S1) ◽  
Author(s):  
Oreoluwa O Coker‐Ayo ◽  
Samuel Nathaniel ◽  
Chika Onuoha ◽  
Nneoma Madubuike ◽  
Lidadi Agbomi ◽  
...  
Keyword(s):  
Gender Differences ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Regression Models ◽  
Operating Characteristic ◽  
Management Strategies ◽  
Roc Curve Analysis ◽  
Alzheimer Dementia ◽  
Dementia Patients ◽  
Specific Factors

Introduction : The role that specific clinical factors play in contributing to gender differences in Alzheimer’s patients with mild cognitive impairment (MCI) is not yet fully understood. In this study, we tested the hypothesis that pharmacological, demographic, and risk factors may contribute to gender difference in Alzheimer’s patients with MCI. Methods : Methods Data collected for 5 years was analyzed using a retrospective data analytical approach on 33,064 Alzheimer patients, including 13,569 men and 19,495 women that presented with MCI. Receiver operating characteristic (ROC) curve analysis and multivariate regression models were used to identify specific factors that contribute to gender differences in MCI patients. Results : Results Our records indicate that women that presented with MCI were more likely to be taking Buspirone (OR = 0.767, 95% CI, 0.683‐0.861, P<0.001) while men within this population were more likely to be taking Galantamine (OR = 0.559, 95% CI, 0.382‐0.818, P<0.001). ETOH use was associated with MCI in both men (OR = 0.696, 95% CI, 0.638‐0.760, P<0.001) and women with Alzheimer’s Dementia (OR = 0.484, 95% CI, 0.442‐0.529, P<0.001). Conclusions : Conclusion Our findings reveal gender differences in men and women that presented with MCI. Management strategies should consider identified factors to provide better care for Alzheimer patients with MCI.

scholarly journals Development of a Sex-Specific Risk Scoring System for Predicting Cognitive Normal to Mild Cognitive Impairment (SRSS-CNMCI)

2021 ◽  
Author(s):  
Wen Luo ◽  
Hao Wen ◽  
Shuqi Ge ◽  
Chunzhi Tang ◽  
Xiufeng Liu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Scoring System ◽  
External Validation ◽  
Scoring Systems ◽  
Cutoff Point ◽  
Risk Scoring ◽  
Risk Scoring System

Abstract Objective: We aim to develop a sex-specific risk scoring system for predicting cognitive normal (CN) to mild cognitive impairment (MCI), abbreviated SRSS-CNMCI, to provide a reliable tool for the prevention of MCI.Methods: Participants aged 61-90 years old with a baseline diagnosis of CN and an endpoint diagnosis of MCI were screened from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database with at least one follow-up. Multivariable Cox proportional hazards models were used to identify risk factors associated with conversion from CN to MCI and to build risk scoring systems for male and female groups. Receiver operating characteristic (ROC) curve analysis was applied to determine the risk probability cutoff point corresponding to the optimal prediction effect. We ran an external validation of the discrimination and calibration based on the Harvard Aging Brain Study (HABS) database.Results: A total of 471 participants, including 240 women (51%) and 231 men (49%), aged 61 to 90 years, were included in the study cohort for subsequent primary analysis. The final multivariable models and the risk scoring systems for females and males included age, APOE ε4, Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). The scoring systems for females and males revealed C statistics of 0.902 (95% CI 0.840-0.963) and 0.911 (95% CI 0.863-0.959), respectively, as measures of discrimination. The cutoff point of high and low risk was 33% in females, and more than 33% was considered high risk, while more than 9% was considered high risk for males. The external validation effect of the scoring systems was good: C statistic 0.950 for the females and C statistic 0.965 for the males. Conclusions: Our parsimonious model accurately predicts conversion from CN to MCI with four risk factors and can be used as a predictive tool for the prevention of MCI.

scholarly journals Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Philipp Spitzer ◽  
Heinke Schieb ◽  
Heike Kamrowski-Kruck ◽  
Markus Otto ◽  
Davide Chiasserini ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Mitogen Activated Protein Kinase ◽  
Fluid Sample ◽  
Alzheimer Dementia ◽  
Extracellular Signal Regulated Kinase ◽  
Total Tau ◽  
Extracellular Signal ◽  
Mitogen Activated Protein

Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.

scholarly journals Age-specific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites

2012 ◽  
Vol 26 (4) ◽  
pp. 335-343 ◽  
Author(s):  
Mindy J. Katz ◽  
Richard B. Lipton ◽  
Charles B. Hall ◽  
Molly E. Zimmerman ◽  
Amy E. Sanders ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Alzheimer Dementia ◽  
Blacks And Whites

scholarly journals Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment

2007 ◽  
Vol 64 (3) ◽  
pp. 366 ◽  
Author(s):  
Anja H. Simonsen ◽  
James McGuire ◽  
Oskar Hansson ◽  
Henrik Zetterberg ◽  
Vladimir N. Podust ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Alzheimer Dementia ◽  
Cerebrospinal Fluid Biomarkers

scholarly journals Plasma Glial Fibrillary Acidic Protein Detects Alzheimer Pathology and Predicts Future Conversion to Alzheimer Dementia in Patients With Mild Cognitive Impairment

2020 ◽  
Author(s):  
Claudia Cicognola ◽  
Shorena Janelidze ◽  
Joakim Hertze ◽  
Henrik Zetterberg ◽  
Kaj Blennow ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Glial Fibrillary Acidic Protein ◽  
Acidic Protein ◽  
Alzheimer Dementia ◽  
Total Tau ◽  
Subsequent Conversion ◽  
Astroglial Activation ◽  
T Tau

Abstract IntroductionPlasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer’s disease (AD) pathology in the form of AD-related amyloid-b (Aβ) pathology and conversion to AD dementia in a mild cognitive impairment (MCI) cohort.Method160 MCI patients were followed for 4.7 years (average). AD pathology was defined using cerebrospinal fluid (CSF) Aβ42/40 and Aβ42/total tau. Plasma GFAP was measured at baseline and follow-up using Simoa technology.ResultsBaseline plasma GFAP could detect abnormal CSF Aβ42/40 and CSF Aβ42/total tau (T-tau) with an AUC of 0.79 (95% CI 0.72-0.86) and 0.80 (95% CI 0.72-0.86), respectively. Combination with APOE ε4 status improved the diagnostic accuracy for abnormal CSF Aβ42/40 status (AUC=0.86, p=0.02). Plasma GFAP predicted subsequent conversion to AD dementia with an AUC of 0.84 (95% CI 0.77-0.91), which was not significantly improved when combined with APOE ε4 or age. Longitudinal GFAP slopes for Aβ-positive and MCI who progressed to AD dementia were significantly steeper than for Aβ-negative (p=0.007) and stable MCI (p<0.0001).ConclusionPlasma GFAP can detect AD pathology in patients with MCI and predict conversion to AD dementia.

Sign in / Sign up

Export Citation Format

Share Document